Similarly, elimination of the BCR-ABL fusion protein through autophagy has been shown in CML, where imatinib has the dual effects of inhibiting the tyrosine kinase activity of BCR-ABL, and inducing its degradation [59]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.